Athena Countouriotis Turning Point Therapeutics, Inc. (TPTX) insider trading activity

Athena Countouriotis is President & CEO of Turning Point Therapeutics, Inc.. Currently has a direct ownership of 0 shares of TPTX, which is worth approximately $0. The most recent transaction as insider was on Aug 17, 2022, when has been sold 110,959 shares (Common Stock) at a price of $76.0 per share, resulting in proceeds of $8,432,884. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Athena Countouriotis Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 17 2022	SELL Sale (or disposition) back to the issuer	$8,432,884 $76.0 p/Share	110,959 Reduced 100.0%	0 Common Stock
Feb 09 2022	SELL Open market or private sale	$107,847 $36.3 p/Share	2,971 Reduced 5.84%	47,930 Common Stock
Feb 09 2022	BUY Grant, award, or other acquisition	-	62,400 Added 36.13%	110,330 Common Stock
Feb 11 2021	SELL Open market or private sale	$1,229,972 $137.55 p/Share	8,942 Reduced 15.12%	50,195 Common Stock
Feb 11 2021	BUY Exercise of conversion of derivative security	$28,614 $3.2 p/Share	8,942 Added 13.13%	59,137 Common Stock
Feb 10 2021	SELL Open market or private sale	$3,464,230 $136.43 p/Share	25,392 Reduced 33.59%	50,195 Common Stock
Feb 10 2021	BUY Exercise of conversion of derivative security	$81,254 $3.2 p/Share	25,392 Added 25.15%	75,587 Common Stock
Feb 09 2021	SELL Open market or private sale	$3,554,484 $138.49 p/Share	25,666 Reduced 33.83%	50,195 Common Stock
Feb 09 2021	BUY Exercise of conversion of derivative security	$82,131 $3.2 p/Share	25,666 Added 25.28%	75,861 Common Stock
Feb 08 2021	BUY Grant, award, or other acquisition	-	22,617 Added 31.06%	50,195 Common Stock
May 21 2020	BUY Open market or private purchase	$249,960 $60.0 p/Share	4,166 Added 13.42%	26,872 Common Stock
Dec 10 2019	BUY Grant, award, or other acquisition	$21,978 $31.13 p/Share	706 Added 3.02%	22,706 Common Stock
Sep 10 2019	BUY Open market or private purchase	$450,000 $45.0 p/Share	10,000 Added 31.25%	22,000 Common Stock
Apr 22 2019	BUY Open market or private purchase	$216,000 $18.0 p/Share	12,000 Added 50.0%	12,000 Common Stock

Also insider at

PASG

Passage BIO, Inc. Healthcare

IOVA

IOVANCE BIOTHERAPEUTICS, INC. Healthcare

Director

BMRN

BIOMARIN PHARMACEUTICAL INC Healthcare

Director